Compare · DXCM vs SGHT
DXCM vs SGHT
Side-by-side comparison of DexCom Inc. (DXCM) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 116.1x SGHT ($242.1M).
- Over the past year, DXCM is down 10.1% and SGHT is up 12.1% - SGHT leads by 22.1 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 8 for SGHT).
- DXCM has more recent analyst coverage (25 ratings vs 19 for SGHT).
- Company
- DexCom Inc.
- Sight Sciences Inc.
- Price
- $76.94+5.63%
- $4.55+1.79%
- Market cap
- $28.11B
- $242.1M
- 1M return
- +26.41%
- -13.83%
- 1Y return
- -10.07%
- +12.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 26
- 8
- Recent ratings
- 25
- 19
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest SGHT
- Director Fountain Tamara was granted 28,261 shares, increasing direct ownership by 35% to 109,650 units (SEC Form 4)
- Director Encrantz Staffan was granted 28,261 shares, increasing direct ownership by 2% to 1,420,183 units (SEC Form 4)
- Director Burbach Gerhard F was granted 28,261 shares, increasing direct ownership by 30% to 123,207 units (SEC Form 4)
- Director Zurbay Donald was granted 28,261 shares, increasing direct ownership by 17% to 193,613 units (SEC Form 4)
- Director Mazzacco Catherine was granted 28,261 shares, increasing direct ownership by 69% to 69,276 units (SEC Form 4)
- Sight Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SD filed by Sight Sciences Inc.
- Chief Operating Officer Bauerlein Alison sold $65,167 worth of shares (12,728 units at $5.12), decreasing direct ownership by 2% to 688,893 units (SEC Form 4)
- SEC Form 10-Q filed by Sight Sciences Inc.
- Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits